Alphatec Holdings, Inc. $ATEC Shares Acquired by Cwm LLC

Cwm LLC lifted its holdings in shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) by 13.4% during the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 35,540 shares of the medical technology company’s stock after acquiring an additional 4,204 shares during the period. Cwm LLC’s holdings in Alphatec were worth $394,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Oppenheimer Asset Management Inc. raised its position in shares of Alphatec by 13.4% during the 1st quarter. Oppenheimer Asset Management Inc. now owns 13,144 shares of the medical technology company’s stock worth $133,000 after acquiring an additional 1,552 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. increased its position in Alphatec by 4.6% during the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 40,734 shares of the medical technology company’s stock worth $413,000 after buying an additional 1,792 shares during the period. Wealth Enhancement Advisory Services LLC increased its position in Alphatec by 4.0% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 62,376 shares of the medical technology company’s stock worth $686,000 after buying an additional 2,389 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Alphatec by 4.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 74,005 shares of the medical technology company’s stock worth $750,000 after buying an additional 3,196 shares during the period. Finally, Belpointe Asset Management LLC increased its position in Alphatec by 23.3% during the first quarter. Belpointe Asset Management LLC now owns 18,500 shares of the medical technology company’s stock worth $188,000 after buying an additional 3,500 shares during the period. Institutional investors and hedge funds own 66.35% of the company’s stock.

Insider Activity at Alphatec

In other Alphatec news, EVP David Sponsel sold 2,555 shares of the business’s stock in a transaction on Friday, September 19th. The stock was sold at an average price of $15.34, for a total transaction of $39,193.70. Following the sale, the executive vice president directly owned 531,861 shares in the company, valued at approximately $8,158,747.74. The trade was a 0.48% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Mortimer Berkowitz III sold 62,500 shares of the business’s stock in a transaction on Tuesday, September 9th. The stock was sold at an average price of $15.97, for a total value of $998,125.00. Following the sale, the director owned 618,050 shares in the company, valued at approximately $9,870,258.50. The trade was a 9.18% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 780,575 shares of company stock valued at $11,769,527 in the last 90 days. 20.90% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several research analysts have commented on the company. Canaccord Genuity Group reaffirmed a “buy” rating and set a $20.00 price target on shares of Alphatec in a research report on Friday, August 1st. Barclays reaffirmed an “overweight” rating and set a $22.00 price target (up previously from $21.00) on shares of Alphatec in a research report on Monday, August 4th. Wells Fargo & Company lifted their price target on Alphatec from $14.00 to $16.00 and gave the stock an “overweight” rating in a research report on Thursday, October 16th. JPMorgan Chase & Co. assumed coverage on Alphatec in a research report on Friday. They set an “overweight” rating and a $19.00 price target on the stock. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Alphatec in a research report on Tuesday, October 14th. Eight equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $18.25.

Alphatec Stock Up 1.4%

Alphatec stock opened at $16.11 on Friday. The company has a debt-to-equity ratio of 23.22, a current ratio of 2.88 and a quick ratio of 1.77. Alphatec Holdings, Inc. has a 1-year low of $5.18 and a 1-year high of $16.70. The company has a market cap of $2.38 billion, a PE ratio of -14.26 and a beta of 1.05. The stock’s 50 day moving average price is $15.17 and its 200 day moving average price is $13.00.

Alphatec (NASDAQ:ATEC) last posted its earnings results on Thursday, July 31st. The medical technology company reported $0.02 EPS for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.08. The firm had revenue of $185.54 million for the quarter, compared to analysts’ expectations of $178.85 million. The firm’s revenue for the quarter was up 27.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.29) earnings per share. Alphatec has set its FY 2025 guidance at EPS. On average, sell-side analysts predict that Alphatec Holdings, Inc. will post -1.08 EPS for the current fiscal year.

Alphatec Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.